The weekly litigation news digest is live. Subscribe now

IP Verse

Pharmaceutical Composition, Methods For Treating And Uses Thereof - EP3539540

The patent EP3539540 was granted to Boehringer Ingelheim on Dec 18, 2024. The application was originally filed on Nov 7, 2011 under application number EP19163940A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3539540

BOEHRINGER INGELHEIM
Application Number
EP19163940A
Filing Date
Nov 7, 2011
Status
Granted And Under Opposition
Nov 15, 2024
Publication Date
Dec 18, 2024
External Links
Slate, Register, Google Patents

Patent Summary

A pharmaceutical composition for preventing, treating, or reducing the risk of hypoglycemia in patients with diabetes, comprising an SGLT2 inhibitor and an insulin, administered in combination or alternation. The composition is particularly effective in patients with type 1 diabetes, where it can reduce the risk of hypoglycemia and improve glycemic control. The SGLT2 inhibitor works by inhibiting glucose reabsorption in the kidneys, while the insulin provides glucose-lowering effects. The combination of the two can prolong the duration of insulin efficacy, reduce the required insulin dose, and prevent or delay the progression of diabetes complications.

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR REDDYS LABORATORIES UK BETAPHARM ARZNEIMITTELSep 18, 2025MAIWALDADMISSIBLE
ELENDSep 18, 2025JOHNSONADMISSIBLE
GENERICS UKSep 18, 2025TER MEER STEINMEISTER & PARTNERADMISSIBLE
SANDOZSep 18, 2025ELKINGTON AND FIFEADMISSIBLE
STADA ARZNEIMITTELSep 18, 2025KERNEBECKADMISSIBLE
POLPHARMASep 17, 2025ELKINGTON AND FIFEADMISSIBLE
HAMM & WITTKOPPSep 16, 2025HAMM & WITTKOPPADMISSIBLE
WUESTHOFF & WUESTHOFFSep 16, 2025SONNENHAUSERADMISSIBLE
CAMULONSep 15, 2025REDDIE & GROSEADMISSIBLE
TEVA PHARMACEUTICALSSep 12, 2025KRAUS & LEDERER PARTGMBBADMISSIBLE
BARDEHLE PAGENBERGSep 10, 2025BARDEHLE PAGENBERG SLADMISSIBLE

Patent Citations (50) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1213296
DESCRIPTIONEP1344780
DESCRIPTIONEP1354888
DESCRIPTIONEP1489089
DESCRIPTIONWO0127128
DESCRIPTIONWO03099836
DESCRIPTIONWO2004007517
DESCRIPTIONWO2004080990
DESCRIPTIONWO2005012326
DESCRIPTIONWO2005092877
DESCRIPTIONWO2006034489
DESCRIPTIONWO2006064033
DESCRIPTIONWO2006117359
DESCRIPTIONWO2006117360
DESCRIPTIONWO2006120208
DESCRIPTIONWO2007025943
DESCRIPTIONWO2007028814
DESCRIPTIONWO2007031548
DESCRIPTIONWO2007093610
DESCRIPTIONWO2007114475
DESCRIPTIONWO2007128749
DESCRIPTIONWO2007140191
DESCRIPTIONWO2008002824
DESCRIPTIONWO2008006496
DESCRIPTIONWO2008013280
DESCRIPTIONWO2008020011
DESCRIPTIONWO2008049923
DESCRIPTIONWO2008055870
DESCRIPTIONWO2008055940
DESCRIPTIONWO2008069327
DESCRIPTIONWO2008116179
DESCRIPTIONWO2009035969
DESCRIPTIONWO2009087081
DESCRIPTIONWO2009087082
DESCRIPTIONWO2009152128
DESCRIPTIONWO2010092124
DESCRIPTIONWO2010092126
OPPOSITIONUS2007249544
OPPOSITIONUS7579449
OPPOSITIONWO2005092877
OPPOSITIONWO2006034489
OPPOSITIONWO2006117359
OPPOSITIONWO2008055940
OPPOSITIONWO2008116179
OPPOSITIONWO2010092123
OPPOSITIONWO2010092126
OPPOSITIONWO2012062698
SEARCHWO2006034489
SEARCHWO2008055940
SEARCHWO2008116179

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents